MEA Psychedelic Drugs Market - Industry Trends and Forecast to 2029

Middle East and Africa psychedelic drugs market is projected to register a substantial CAGR of 11.2% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2020 and the forecast period is 2022 to 2029.

Market Segmentation: 

Middle East and Africa Psychedelic Drugs market, By Source (Synthetic & Natural), Type (Empathogens, Dissociatives & Others), Drugs (Gamma-Hydroxybutyric Acid, Ketamine, Psilocybin & Others), Application (Narcolepsy, Treatment Resistant Depression, Major Depressive Disorder, Opiate Addiction, Post-Traumatic Stress Disorder & Others), Route of Administration (Oral, Inhalation & Injectable), End User (Hospitals, Specialty Clinics, Homecare & Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy & Online Pharmacy), Country (Saudi Arabia, Israel, Egypt, UAE, South Africa and Rest of Middle East and Africa). Market Trends and Forecast to 2029

Some of the major factors contributing to the growth of the Middle East and Africa psychedelic drugs market are:

• Rise in product approvals

• Ongoing clinical trials

Market Players:

The key market players for Middle East and Africa psychedelic drugs market are listed below:

• Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.)
• Hikma Pharmaceuticals PLC
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• Jazz Pharmaceuticals, Inc.